HC Wainwright Has Positive Estimate for AGMB FY2026 Earnings

AgomAb Therapeutics NV (NASDAQ:AGMB) – HC Wainwright increased their FY2026 EPS estimates for AgomAb Therapeutics in a research note issued on Tuesday, October 20th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.91) for the year, up from their prior estimate of ($1.96). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for AgomAb Therapeutics’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for AgomAb Therapeutics’ FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($1.75) EPS, FY2029 earnings at ($1.81) EPS and FY2030 earnings at ($1.79) EPS.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter.

Several other research analysts have also commented on AGMB. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Johnson Rice restated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday. B. Riley Financial assumed coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. Piper Sandler assumed coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating on the stock. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ AGMB opened at $9.26 on Friday. The firm’s 50-day moving average price is $11.60 and its 200-day moving average price is $11.77. AgomAb Therapeutics has a 12-month low of $7.92 and a 12-month high of $17.82.

Insider Buying and Selling

In other news, CFO Pierre Kemula purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were bought at an average cost of $8.59 per share, for a total transaction of $85,900.00. Following the acquisition, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $85,900. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Epstein purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The shares were purchased at an average price of $8.88 per share, for a total transaction of $88,800.00. Following the completion of the acquisition, the director directly owned 25,000 shares in the company, valued at $222,000. The trade was a 66.67% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 41,000 shares of company stock valued at $357,080.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.